BackgroundThe development of interactive rehabilitation technologies which rely on wearable-sensing for upper body rehabilitation is attracting increasing research interest. This paper reviews related research with the aim: 1) To inventory and classify interactive wearable systems for movement and posture monitoring during upper body rehabilitation, regarding the sensing technology, system measurements and feedback conditions; 2) To gauge the wearability of the wearable systems; 3) To inventory the availability of clinical evidence supporting the effectiveness of related technologies.MethodA systematic literature search was conducted in the following search engines: PubMed, ACM, Scopus and IEEE (January 2010–April 2016).ResultsForty-five papers were included and discussed in a new cuboid taxonomy which consists of 3 dimensions: sensing technology, feedback modalities and system measurements. Wearable sensor systems were developed for persons in: 1) Neuro-rehabilitation: stroke (n = 21), spinal cord injury (n = 1), cerebral palsy (n = 2), Alzheimer (n = 1); 2) Musculoskeletal impairment: ligament rehabilitation (n = 1), arthritis (n = 1), frozen shoulder (n = 1), bones trauma (n = 1); 3) Others: chronic pulmonary obstructive disease (n = 1), chronic pain rehabilitation (n = 1) and other general rehabilitation (n = 14). Accelerometers and inertial measurement units (IMU) are the most frequently used technologies (84% of the papers). They are mostly used in multiple sensor configurations to measure upper limb kinematics and/or trunk posture. Sensors are placed mostly on the trunk, upper arm, the forearm, the wrist, and the finger. Typically sensors are attachable rather than embedded in wearable devices and garments; although studies that embed and integrate sensors are increasing in the last 4 years. 16 studies applied knowledge of result (KR) feedback, 14 studies applied knowledge of performance (KP) feedback and 15 studies applied both in various modalities. 16 studies have conducted their evaluation with patients and reported usability tests, while only three of them conducted clinical trials including one randomized clinical trial.ConclusionsThis review has shown that wearable systems are used mostly for the monitoring and provision of feedback on posture and upper extremity movements in stroke rehabilitation. The results indicated that accelerometers and IMUs are the most frequently used sensors, in most cases attached to the body through ad hoc contraptions for the purpose of improving range of motion and movement performance during upper body rehabilitation. Systems featuring sensors embedded in wearable appliances or garments are only beginning to emerge. Similarly, clinical evaluations are scarce and are further needed to provide evidence on effectiveness and pave the path towards implementation in clinical settings.

A607changes in treatments' effect on weight and HbA1c, and in utility values related to weight changes. Dapagliflozin's higher health benefits and cost savings are mainly explained by its greater beneficial effect on weight, leading to higher QALYs and less drug costs for dapagliflozin patients. The lower treatment costs are related to the insulin treatment costs (i.e. subsequent line regimens) due to the lower weight of dapagliflozin patients observed over time, which eventually leads to lesser insulin dosage. ConClusions: Dapagliflozin is a cost-saving strategy with higher health benefits compared to DPP4, added to metformin, for Turkish T2DM patients inadequately controlled on metformin mono-therapy.

S63 and prevention age (until 5 years old), with a diagnosis of gastroenteritis (ICD-10th codes: A08 (viral and other intestinal infections), A09 (diarrhea and gastroenteritis of infectious origin)) from the National Health Insurance claims data. The annual prevalence rate of RVGE was calculated as the product of the number of gastroenteritis patients and the detection rate of RV among children with gastroenteritis under 5, retrieved from EnterNet, the national laboratory surveillance of acute gastroenteritis in Korea. The burden of RVGE was estimated from a restricted societal perspective including medical, non-medical and productivity loss costs due to morbidity. Annual national costs associated with RVGE were derived by multiplying the average cost per patient with RV-specific code (A08.0: rotaviral enteritis) by the estimated number of patients attributable to RV infection. All costs were expressed in 2015 US dollars (1 USD = 1,100 Korean won). RESULTS: Compared to pre-vaccination period, the prevalence rate constantly decreased in the post-vaccination period, implying an increase in the coverage rate of RV vaccination and in herd immunity. The prevalence rate of RVGE per 100,000 children fell from 5784.

Background: Extracellular matrix degradation, mediated by the urokinase plasminogen activation (uPA) system, is a critical step in tumor invasion and metastasis. High tumor level of uPA has been correlated with poor cancer prognosis. We examined the single nucleotide polymorphisms (SNPs) with a potential effect on expression of genes in the uPA system for their role in non−small cell lung cancer susceptibility. Patients and methods: We compared the genotype distributions of each SNP in the promoter regions of uPA rs4065 T/C and uPAR rs344781−516 A/G in 363 NSCLC cases and 330 controls using polymerase chain reaction−restriction fragment−length polymorphism analysis. Results: Overall, there were significant differences in the genotype distributions between cases and controls . The distribution of the genotype frequencies of uPA rs4065 T/C (p = 0.001) and uPAR rs344781−516 A/G (p = 0.004) were significantly different between the lung cancer patients and the healthy controls. Logistic regression analysis revealed that higher odds ratios (ORs) for lung cancer were seen for individuals with uPA rs4065 TT genotype against CC/CT genotypes (an OR of 6.02, 95% CI 1.77−20.5, p = 0.001), and lower odds ratios (ORs) for lung cancer were seen for individuals with uPAR−344781−516 AA genotype against GG/GA genotypes (an OR of 0.50, 95% CI 0.35−0.72, p < 0.0001). Conclusions: A significant association between the uPA rs4065 T/C and uPAR rs344781−516 A/G genetic polymorphisms and the susceptibility to lung cancer was demonstrated. The uPA TT genotype has a promotive effect for lung cancer development, whereas the uPAR AA genotype has a protective function against lung cancers. This abstract is funded by: None.

Probabilistic sensitivity analyses showed that the ICER changed under various scenarios, but in the majority of cases remained below the threshold. ConClusions: Rituximab plus CHOP is a highly effective and well tolerated regimen for the treatment of DLBCL. R-CHOP is more cost-effective than CHOP-regimen for the Chinese health insurance system.